First drug to slow Alzheimer’s progression won't be made available on the NHS as it is too expensive
NHS spending watchdog said the benefits of lecanemab in slowing the condition are ‘just too small to justify the significant cost’
NHS spending watchdog said the benefits of lecanemab in slowing the condition are ‘just too small to justify the significant cost’